Company Overview
Company Type: Private Company
Website: mesentech.com
Number of Employees: -
Year Founded: 2013
Total Amount Raised (CAD mm)†: 4.91
Total Rounds of Funding**:2
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Mesentech Inc. is a regenerative medicine company with a prodrug platform that selectively delivers therapeutics to bone. The company makes bi-specific small-molecule therapeutics that are selective for a tissue target and a molecular target. Its conjugates deliver an active pharmaceutical agent selectively to target tissue thereby eliminating side effects caused by systemic exposure. Its products include MES1007, a bone-targeted prodrug of a prostaglandin mimetic that has the potential to reverse bone-loss caused by diseases, such as Duchenne muscular dystrophy and osteoporosis. The company was incorporated in 2013 and is based in Vancouver, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Polak, Jonathan 
CEO & Director
Young, Robert Norman
Founder, President & Director
Cullis, Pieter 
Founder
Rossi, Fabio 
Founder
Underhill, Michael 
Founder & Advisor
Tam, Pat 
Chief Development Officer

Key Board Members
Name
Title
Polak, Jonathan 
CEO & Director
Young, Robert Norman
Founder, President & Director
Dvorak, David Carr
Director
Hu, Ruoxi 
Director
Kelly, Michael G.
Member of Scientific Advisory Board
Mohr, Joseph S.
Director
Wu, Samuel 
Director
Yanni, Barbara 
Director


Primary Industry Classification
Biotechnology


Primary Office Location
2222 Health Sciences Mall | Vancouver, BC | V6T 1Z3 | Canada
Phone: 774 234 8018   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
CureDuchenne
Nov-10-2020
Minority
-
Venture
Anchor Advisors Inc., Investment Arm
-
Unknown
-
-
CCRM Enterprises Inc.
-
Unknown
-
-


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Mar-31-2022
Apr-14-2022
Private Placement
Target
Mesentech Inc.


3.89
Nov-10-2020
Nov-10-2020
Private Placement
Target
Mesentech Inc.
CureDuchenne

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-26-2023
Product-Related Announcements
Mesentech Doses First Patients with Investigational Drug MES1022 to Accelerate Healing of Bone Fractures
Mar-20-2023
Company Conference Presentations
Mesentech Inc. Presents at BIO-Europe Spring 2023, Mar-20-2023
Jan-09-2023
Company Conference Presentations
Mesentech Inc. Presents at BIO Partnering at JPM 2023, Jan-09-2023
Apr-14-2022
Private Placements
Mesentech Inc. announced that it has received $3.891947 million in funding
Mar-31-2022
Private Placements
Mesentech Inc. announced a financing transaction


Last 10 Investment Research Documents
No Investment Research returned. This can be caused by entitlement settings or your template settings.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Polak, Jonathan 
CEO & Director
(416) 774-8018
-
jpolak@mesentech.com
Young, Robert Norman
Founder, President & Director
774 234 8018
-

Dvorak, David Carr
Director
774 234 8018
-

Hu, Ruoxi 
Director
774 234 8018
-

Kelly, Michael G.
Member of Scientific Advisory Board
774 234 8018
-
michael@cureduchenne.org
Mohr, Joseph S.
Director
(617) 318-3422
-

Wu, Samuel 
Director
774 234 8018
-

Yanni, Barbara 
Director
774 234 8018
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Polak, Jonathan 
CEO & Director
(416) 774-8018
-
jpolak@mesentech.com
Young, Robert Norman
Founder, President & Director
774 234 8018
-

Cullis, Pieter 
Founder
774 234 8018
-

Rossi, Fabio 
Founder
774 234 8018
-

Underhill, Michael 
Founder & Advisor
774 234 8018
-

Tam, Pat 
Chief Development Officer
774 234 8018
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
